 Connection
Paul Bunn to Prognosis
This is a "connection" page, showing publications Paul Bunn has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.879 |
|
|
|
-
Bunn PA, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res. 2014 Apr 01; 20(7):1727-9.
Score: 0.263
-
Bunn PA, Kim ES. Improving the Care of Patients With Stage IB Non-Small-Cell Lung Cancer: Role of Prognostic Signatures and Use of Cell Cycle Progression Biomarkers. Clin Lung Cancer. 2015 Jul; 16(4):245-51.
Score: 0.071
-
Bunn PA. Optimal therapy for elderly patients with early stage non-small cell lung cancer. Am J Respir Crit Care Med. 2010 Feb 01; 181(3):201-2.
Score: 0.050
-
Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006 Jan 15; 66(2):944-50.
Score: 0.038
-
Bunn PA, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S175-86.
Score: 0.032
-
Hirsch FR, Franklin WA, Bunn PA. What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? Lung Cancer. 2002 Jun; 36(3):263-4.
Score: 0.029
-
Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002 May 06; 86(9):1449-56.
Score: 0.029
-
Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment? Chest. 2000 Apr; 117(4 Suppl 1):119S-122S.
Score: 0.025
-
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):e191-e204.
Score: 0.024
-
Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Dec; 13(12):1818-1831.
Score: 0.023
-
Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clin Cancer Res. 2018 03 01; 24(5):1038-1047.
Score: 0.021
-
He Y, Bunn PA, Zhou C, Chan D. KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer. Oncotarget. 2016 Dec 13; 7(50):82104-82111.
Score: 0.020
-
Peled N, Zach L, Liran O, Ilouze M, Bunn PA, Hirsch FR. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol. 2013 Dec; 8(12):e112-3.
Score: 0.016
-
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(12):1807-1814.
Score: 0.015
-
Peled N, Hakim M, Bunn PA, Miller YE, Kennedy TC, Mattei J, Mitchell JD, Hirsch FR, Haick H. Non-invasive breath analysis of pulmonary nodules. J Thorac Oncol. 2012 Oct; 7(10):1528-33.
Score: 0.015
-
Varella-Garcia M, Mitsudomi T, Yatabe Y, Kosaka T, Nakajima E, Xavier AC, Skokan M, Zeng C, Franklin WA, Bunn PA, Hirsch FR. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. J Thorac Oncol. 2009 Mar; 4(3):318-25.
Score: 0.012
-
Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7.
Score: 0.011
-
Bunn PA. Diagnostic factors in intermediate and high-grade lymphomas: pathologic, immunologic, and clinical. J Clin Oncol. 1988 Jul; 6(7):1073-5.
Score: 0.011
-
Weiss GJ, Vokes EE, Bunn PA, Magree L, Rusk J, Albert D, Kelly K. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
Score: 0.011
-
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007 Jun 06; 99(11):838-46.
Score: 0.010
-
Bunn PA, Lichter AS, Makuch RW, Cohen MH, Veach SR, Matthews MJ, Anderson AJ, Edison M, Glatstein E, Minna JD, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med. 1987 May; 106(5):655-62.
Score: 0.010
-
Bunn PA, Greco FA, Einhorn L. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer. Semin Oncol. 1986 Sep; 13(3 Suppl 3):45-53.
Score: 0.010
-
Kuefler PR, Bunn PA. Adult T cell leukaemia/lymphoma. Clin Haematol. 1986 Aug; 15(3):695-726.
Score: 0.010
-
Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005 Dec 12; 93(12):1334-40.
Score: 0.009
-
Sausville EA, Worsham GF, Matthews MJ, Makuch RW, Fischmann AB, Schechter GP, Gazdar AF, Bunn PA. Histologic assessment of lymph nodes in mycosis fungoides/S?zary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol. 1985 Nov; 16(11):1098-109.
Score: 0.009
-
Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Bar?n AE, Zeng C, Franklin WA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003 Oct 15; 21(20):3798-807.
Score: 0.008
-
Winkler CF, Bunn PA. Cutaneous T-cell lymphoma: a review. Crit Rev Oncol Hematol. 1983; 1(1):49-92.
Score: 0.008
-
Bunn PA, Krasnow S, Makuch RW, Schlam ML, Schechter GP. Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. Blood. 1982 Mar; 59(3):528-35.
Score: 0.007
-
Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, Glatstein EJ, Wiernik PH, Lichter AS, Bunn PA. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore). 1982 Jan; 61(1):45-53.
Score: 0.007
-
Hirsch FR, Prindiville SA, Miller YE, Franklin WA, Dempsey EC, Murphy JR, Bunn PA, Kennedy TC. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst. 2001 Sep 19; 93(18):1385-91.
Score: 0.007
-
Posner LE, Fossieck BE, Eddy JL, Bunn PA. Septicemic complications of the cutaneous T-cell lymphomas. Am J Med. 1981 Aug; 71(2):210-6.
Score: 0.007
-
Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100.
Score: 0.007
-
Broder S, Bunn PA. Cutaneous T-cell lymphomas. Semin Oncol. 1980 Sep; 7(3):310-31.
Score: 0.006
-
Carney DN, Bunn PA. Manifestations of cutaneous T-cell lymphoma. J Dermatol Surg Oncol. 1980 May; 6(5):369-77.
Score: 0.006
-
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998 Mar 15; 58(6):1149-58.
Score: 0.005
-
Bunn PA, Cohen MH, Ihde DC, Fossieck BE, Matthews MJ, Minna JD. Advances in small cell bronchogenic carcinoma. Cancer Treat Rep. 1977 May-Jun; 61(3):333-42.
Score: 0.005
-
Carmichael J, Crane JM, Bunn PA, Glatstein E, Ihde DC. Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys. 1988 Mar; 14(3):455-9.
Score: 0.003
-
Dmitrovsky E, Matthews MJ, Bunn PA, Schechter GP, Makuch RW, Winkler CF, Eddy J, Sausville EA, Ihde DC. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol. 1987 Feb; 5(2):208-15.
Score: 0.003
-
Ihde DC, Deisseroth AB, Lichter AS, Bunn PA, Carney DN, Cohen MH, Veach SR, Makuch RW, Johnston-Early A, Abrams RA, et al. Late intensive combined modality therapy followed by autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol. 1986 Oct; 4(10):1443-54.
Score: 0.002
-
Brooks BJ, Seifter EJ, Walsh TE, Lichter AS, Bunn PA, Zabell A, Johnston-Early A, Edison M, Makuch RW, Cohen MH, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol. 1986 Feb; 4(2):200-9.
Score: 0.002
-
Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984 Apr; 10(4):515-39.
Score: 0.002
-
Brower M, Ihde DC, Johnston-Early A, Bunn PA, Cohen MH, Carney DN, Makuch RW, Matthews MJ, Radice PA, Minna JD. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med. 1983 Dec; 75(6):993-1000.
Score: 0.002
-
Johnston-Early A, Cohen MH, Fossieck BE, Harwood S, Ihde DC, Bunn PA, Matthews MJ, Minna JD, Makuch R. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer. 1983 Oct 15; 52(8):1395-400.
Score: 0.002
-
Radice PA, Matthews MJ, Ihde DC, Gazdar AF, Carney DN, Bunn PA, Cohen MH, Fossieck BE, Makuch RW, Minna JD. The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer. 1982 Dec 15; 50(12):2894-902.
Score: 0.002
-
Whang-Peng J, Bunn PA, Knutsen T, Matthews MJ, Schechter G, Minna JD. Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma (CTCL). Cancer. 1982 Oct 15; 50(8):1539-53.
Score: 0.002
-
Carney DN, Marangos PJ, Ihde DC, Bunn PA, Cohen MH, Minna JD, Gazdar AF. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13; 1(8272):583-5.
Score: 0.002
-
Levenson RM, Sauerbrunn BJ, Ihde DC, Bunn PA, Cohen MH, Minna JD. Small cell lung cancer: radionuclide bone scans for assessment of tumor extent and response. AJR Am J Roentgenol. 1981 Jul; 137(1):31-5.
Score: 0.002
-
Ihde DC, Makuch RW, Carney DN, Bunn PA, Cohen MH, Matthews MJ, Minna JD. Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis. 1981 May; 123(5):500-7.
Score: 0.002
-
Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA, Fossieck BE, Minna JD. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep. 1981 Mar-Apr; 65(3-4):187-95.
Score: 0.002
-
Carney DN, Matthews MJ, Ihde DC, Bunn PA, Cohen MH, Makuch RW, Gazdar AF, Minna JD. Influence of histologic subtype of small cell carcinoma of the lung on clinical presentation, response to therapy, and survival. J Natl Cancer Inst. 1980 Dec; 65(6):1225-30.
Score: 0.002
-
Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE, Ihde DC, Bunn PA, Matthews MJ, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA. 1980 Nov 14; 244(19):2175-9.
Score: 0.002
-
Ihde DC, Simms EB, Matthews MJ, Cohen MH, Bunn PA, Minna JD. Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis. Blood. 1979 Apr; 53(4):677-86.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|